Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S30-S37 , July 2008

Slowing the progression of kidney disease in patients with diabetes

Based on material presented at a Boehringer Ingelheim-Sponsored Meeting held in Madrid, Spain, May 4–5, 2007.

  • Ellen Burgess, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Ellen Burgess, MD, University of Calgary, 1403-29 Street NW, Calgary, Alberta, T2N 2T9 Canada. Tel: 001 403 944 1598; fax: 001 403 283 2494.

References 

  1. Jerums G, MacIsaac RJ. Treatment of microalbuminuria in patients with type 2 diabetes mellitus. Treat Endocrinol. 2002;1:163–173
  2. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85–97
  3. Bakris GL, Whelton P, Weir M, Mimran A, Keane W, Schiffrin E. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference (Evaluation of clinical trial endpoints in chronic renal disease study group). J Clin Pharmacol. 2000;40:815–825
  4. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies (“Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN)). Kidney Int. 1998;53:1209–1216
  5. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004–1010
  6. Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 1993;36:1071–1078
  7. Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:1051–1056
  8. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus (A population-based study in Rochester, Minnesota). Ann Intern Med. 1989;111:788–796
  9. Nelson RG, Knowler WC, McCance DR, Sievers ML, Pettitt DJ, Charles MA, et al. Determinants of end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia. 1993;36:1087–1093
  10. Ordonez JD, Hiatt RA. Comparison of type II and type I diabetics treated for end-stage renal disease in a large prepaid health plan population. Nephron. 1989;51:524–529
  11. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephron Dial Transplant. 1994;9:1097–1102
  12. Pylypchuk G, Beaubien E. Diabetic nephropathy (Prevention and early referral). Can Fam Physician. 2000;46:636–642
  13. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19:403–418
  14. Maher JF. Diabetic nephropathy: early detection, prevention and management. Am Fam Physician. 1992;45:1661–1668
  15. Anderson S, Brenner BM. The role of intraglomerular pressure in the initiation and progression of renal disease. J Hypertens. 1986;4:S236–S238
  16. Selby JV, FitzSimmons SC, Newman JM, Katz PP, Sepe S, Showstack J. The natural history and epidemiology of diabetic nephropathy (Implications for prevention and control). JAMA. 1990;263:1954–1960
  17. Goode NP, Shires M, Crellin DM, Aparicio SR, Davison AM. Alterations of glomerular basement membrane charge and structure in diabetic nephropathy. Diabetologia. 1995;38:1455–1465
  18. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada (Canadian Diabetes Association). CMAJ. 1998;159:S1–S29
  19. Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney (A risk-benefit assessment). Drug Saf. 1996;15:200–211
  20. Eastman RC, Keen H. The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet. 1997;350:S29–S32
  21. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27:2033–2039
  22. Lok CE, Oliver MJ, Rothwell DM, Hux JE. The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant. 2004;19:3098–3103
  23. National Institute of Diabetes and Digestive and Kidney Disease. End-stage renal disease rate stabilizing, USRDS finds. http://kidney.niddk.nih.gov/about/Research_Updates/KidneyDiseaseSum06/1.htmAccessed: May 29, 2007
  24. US Renal Data System: 2002 Annual Data Report. Bethesda, Maryland: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2002;
  25. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holmes RR UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–232
  26. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
  27. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17:S86–S89
  28. Andersen S, Brochner-Mortensen J, Parving H-H Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 2003;26:3296–3302
  29. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–1578
  30. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  31. De Zeeuw D, Remuzzi G, Parving H-H, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–2320
  32. Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens. 2003;21:S37–S46
  33. Bakris G, Burgess E, Davidai G, Koval S, Weir M; the AMADEO Investigators. Influence of Glycemic Control on Proteinuria in Patients with Type 2 Diabetes and Overt Nephropathy and Hypertension: Results of the AMADEO Trial (poster 0601-P). Presented at the 67th Scientific Sessions of the American Diabetes Association, June 22–26, 2007.
  34. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  35. American Diabetes Association. Nephropathy in diabetes (Position statement). Diabetes Care. 2004;27:S79–S83
  36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  37. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2003;26:S94–S98
  38. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl. 2004;66:S50–S55
  39. Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlof B, et al. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens. 2007;25:871–876

 Conflict of interest: none.

PII: S1933-1711(08)00042-9

doi: 10.1016/j.jash.2008.03.007

Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S30-S37 , July 2008

Article Tools

* Image Usage & Resolution